Biolog, Inc.

Biolog, Inc., a for-profit manufacturer headquartered in Hayward, California, sells microbiological testing instruments, growth media, and associated maintenance and support services to federal agencies as a prime contractor. The company competes predominantly in full-and-open procurements without set-aside designation, though it has received two Total Small Business awards in its recent portfolio.

Biolog's capability portfolio centers on proprietary microbial identification and phenotypic analysis systems — principally the OmniLog and MicroStation platforms — along with specialized growth media such as Rainbow Agar O157 used in pathogen screening. The company also manufactures the Odin VIII system for cellular metabolic characterization and fungal identification. Representative recent work includes a $160,965.65 firm fixed-price purchase order from the Food and Drug Administration (awarded August 2026) for an Integrated Dual-Mode Microbial Phenotypic Analysis System with performance in Laurel, Maryland and completion by August 2028; a $107,352 purchase order from the Navy's Bureau of Medicine and Surgery (April 2024) for a Phenotypic Microarray system and Odin installation and training services; and a $157,421.75 purchase order from the CDC Pittsburgh (August 2022) for a Biolog G3 Log Combo system. The company also holds a significant Indefinite Delivery Contract (123A9420D0004) with the USDA Food Safety and Inspection Service valued at $400,000 through May 2025, against which it places recurring delivery orders for Rainbow Agar O157 and related testing media.

Customer concentration is moderate and spread across civilian health and agriculture agencies. The top five customers by count account for 42% of all awards. The FDA leads by both volume and dollars (38 awards, $1.7 million combined potential value), followed by USDA Agricultural Research Service regional components and the USDA Food Safety and Inspection Service. The FDA also anchors the top-customer ranking by potential value, with $1.7 million, while USDA FSIS ranks second at $578 thousand. The company serves 48 distinct federal agencies across its portfolio, indicating broad but dispersed customer relationships rather than concentration with a single agency.

Biolog's award activity has been uneven: 16 awards in 2022, declining to 4 in 2023, recovering to 8 in 2024 and 8 in 2025, and 4 awards recorded through August 2026 (a partial-year snapshot). Combined potential value across all 278 awards in the source is $7.7 million, though combined obligated dollars total $10.2 million, indicating that some orders have been fully drawn against their potential values. Four awards with combined potential value of $232 thousand face ultimate completion inside the next twenty-four months, representing modest recompete exposure relative to the overall portfolio.

The company's work is classified primarily under NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing), with procurement support codes for Laboratory Equipment and Supplies and Maintenance/Repair/Rebuild of Instruments and Laboratory Equipment dominating the award record. Biolog operates as a pure prime contractor — 277 of 278 awards in the source are primes, with a single subcontract appearance under Astrion Group, LLC on a Laboratory Support Services and Operations II (LASSO II) task (April 2025), for which no dollar value is stated.

Biolog has maintained SAM.gov registration since 2002 and does not hold seats on government-wide vehicles (GWACs, IDIQs, or agency-wide blanket purchase agreements) beyond the USDA FSIS single-award IDC noted above. The company's federal footprint reflects specialized product positioning: it competes through direct purchase orders and delivery orders placed by individual agencies and components, typically on a sole-source or competitive basis, with technical specifications calling for Biolog's proprietary systems.